Glucosidase, Alpha, Acid (GAA) Peptide
GAA
适用: 人
宿主: 合成
BP, IHC, WB
-
- 抗原 See all GAA products
- GAA (Glucosidase, Alpha, Acid (GAA))
- 宿主
- 人
-
资源
- 合成
- 应用范围
- Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
- 产品特性
- This is a synthetic peptide designed for use in combination with anti-GAA antibody (Catalog #: ARP44226_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- 纯化方法
- Purified
-
-
- 应用备注
- Each Investigator should determine their own optimal working dilution for specific applications.
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 溶解方式
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- 浓度
- 1 mg/mL
- 缓冲液
- Final peptide concentration is 1 mg/mL in PBS.
- 注意事项
- Avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- 抗原
- GAA (Glucosidase, Alpha, Acid (GAA))
- 背景
-
GAA is acid alpha-glucosidase, which is essential for the degradation of glycogen to glucose in lysosomes. Different forms of acid alpha-glucosidase are obtained by proteolytic processing. Defects in this gene are the cause of glycogen storage disease II, also known as Pompe's disease, which is an autosomal recessive disorder with a broad clinical spectrum. This gene encodes acid alpha-glucosidase, which is essential for the degradation of glycogen to glucose in lysosomes. Different forms of acid alpha-glucosidase are obtained by proteolytic processing. Defects in this gene are the cause of glycogen storage disease II, also known as Pompe's disease, which is an autosomal recessive disorder with a broad clinical spectrum. Three transcript variants encoding the same protein have been found for this gene.
Alias Symbols: LYAG
Protein Interaction Partner: NCF1
Protein Size: 952 - 分子量
- 98 kDa
- 基因ID
- 2548
- NCBI登录号
- NM_000152, NP_000143
- UniProt
- P10253
-
You are here:
